Introduction

Cholesterol medicines have helped many people lower their risk of heart attacks and strokes. Yet some people still face heart risk even when their LDL cholesterol, often called bad cholesterol, is well controlled.

Researchers are now looking beyond LDL to other blood fats and newer treatment options, including medicines given by injection.

This article explains what recent reviews and a large cohort study suggest about these approaches. It also explains what is still unknown, especially for people with advanced kidney disease and other high-risk groups.

What Are Injectable and Triglyceride-Targeted Lipid Therapies?

Lipids are fats that travel through the bloodstream. LDL cholesterol carries cholesterol into artery walls, where it can contribute to plaque buildup.

Triglycerides are another type of blood fat. When they are high, they are carried by particles called triglyceride-rich lipoproteins, and the leftover pieces of these particles are called remnant cholesterol.

Several newer treatments are being studied. Most are given by injection and work through unusual pathways.

Examples include PCSK9 antibodies, inclisiran, and agents that target ANGPTL3, apolipoprotein C-III, or lipoprotein(a) [1,3]. Some of these therapies are already used in clinical practice, while others remain investigational.

Why Does It Matter?

Heart disease is the leading cause of illness and death in people with chronic kidney disease, especially those who need dialysis [1].

Standard treatments may work differently in these patients. Many people with advanced kidney disease are also underrepresented in clinical trials, which makes it harder to know what works best for them [1].

Residual risk is another concern. This term describes the risk that remains after the main known factors have been treated. Reviews suggest that triglyceride-rich particles may contribute to residual risk because they appear to be involved in plaque formation and inflammation [5].

What Does the Latest Research Show?

Lowering LDL Further After Statins

Observational evidence: A multiregional cohort study followed 185,237 adults in Hong Kong, New Zealand, and the United Kingdom who started statins for primary prevention, meaning they had no known heart disease at the start [2].

People whose LDL cholesterol fell to 1.8 to 2.5 mmol/L or 1.4 to 1.7 mmol/L had fewer major adverse cardiovascular events than those who stayed at 2.6 mmol/L or higher [2]. Non-HDL cholesterol showed similar patterns [2].

Because this was an observational study, it cannot prove that lowering these levels caused fewer events. People with lower cholesterol may also have differed in other ways.

The researchers noted this possibility, called confounding by indication, where doctors may have treated higher-risk patients more intensively [2].

Injectable LDL-Lowering Therapy: Inclisiran

Established evidence for LDL lowering: A review of randomized clinical trials reports that inclisiran produces strong and lasting reductions in LDL cholesterol across many patient groups [3].

Inclisiran is a small interfering RNA, a type of molecule that reduces the liver’s production of PCSK9, a protein that removes LDL from the blood [3]. Because it is given twice a year, the review suggests it may help people stay on treatment [3].

Emerging evidence for heart outcomes: The same review reports that long-term safety data extend up to six years and that no dose changes were required in people with kidney or liver impairment [3]. However, the authors state that ongoing outcome trials are needed to show whether inclisiran reduces heart attacks and strokes [3].

Triglyceride-Targeted Therapies

Genetic and observational evidence: People who naturally carry loss-of-function variants in the APOC3 gene tend to have lower triglycerides and reduced cardiovascular risk [4]. This supports apolipoprotein C-III as a biological target, but genetic associations do not prove that drugs targeting it will prevent events [4].

Emerging evidence: RNA-based drugs that reduce apolipoprotein C-III, including volanesorsen, olezarsen, and plozasiran, have lowered triglycerides in studies of rare and severe forms of high triglycerides [4].

In familial chylomicronemia syndrome, these agents reduced both triglycerides and acute pancreatitis, a painful and dangerous inflammation of the pancreas [4].

In moderate hypertriglyceridemia, olezarsen and plozasiran lowered triglycerides, remnant cholesterol, non-HDL cholesterol, and apolipoprotein B [4].

However, an imaging study of olezarsen showed no clear change in coronary plaque composition, and cardiovascular event reduction has not been demonstrated [4].

A separate review notes that icosapent ethyl, a purified form of omega-3 fatty acid, is the only triglyceride-targeted therapy in its analysis to show a significant reduction in major cardiovascular events in a large randomized trial [5].

Older treatments, fibrates and mixed omega-3 formulations, have produced modest and inconsistent cardiovascular benefits [5].

Newer agents such as evinacumab, an ANGPTL3 antibody, and apolipoprotein C-III inhibitors have produced large drops in triglycerides in recent studies, but cardiovascular outcome data are not yet available [5].

How Do These Treatments Work?

Think of LDL and triglyceride particles as cargo trucks moving through the blood. Many new medicines try to slow the trucks from being made, or help the body clear them faster.

• PCSK9 and inclisiran: These help the liver remove more LDL from the blood [1,3].
• Apolipoprotein C-III inhibitors: These reduce a protein that helps control how triglyceride-rich particles are cleared [4].
• ANGPTL3 agents: These target a protein that influences blood fat levels, and they are under study [1,5].

Preclinical and expert interpretation: A review suggests these agents may keep working across stages of kidney disease because their pharmacokinetic profiles, meaning how the body processes them, are largely preserved [1]. This is biologically reasonable, but drug handling in people on dialysis still needs direct study.

Who May Benefit?

Most of the evidence discussed here comes from people with established heart disease, high LDL, familial hypercholesterolemia, or very high triglycerides [3,4].

Researchers are especially interested in people with advanced kidney disease, who face high risk but have been poorly represented in trials [1].

The review on advanced kidney disease notes a feature called the dialysis paradox. In some dialysis patients, lower cholesterol is linked to worse outcomes, possibly due to malnutrition and inflammation [1].

This is one reason expert guidelines differ for dialysis populations [1]. Decisions in this group should be made carefully with a kidney specialist and a cardiologist.

Practical Implications

For most readers, the most useful takeaway is that cholesterol care is becoming more personal. Doctors may consider LDL, non-HDL cholesterol, triglycerides, and other risk markers together.

• Statins remain a central treatment in earlier kidney disease and many other settings [1].
• Non-HDL cholesterol may be a useful target after statin treatment begins, according to observational data [2].
• Injectable and triglyceride-targeted therapies are promising, but many are still being studied for heart outcomes [3,4,5].

Risks and Safety Concerns

Every medicine has possible side effects, and newer treatments need long-term monitoring. Injection site reactions and other effects are reported in trials, but the reviews here do not provide a complete safety picture for every agent. Doctors should weigh benefits and risks for each person.

The observational cohort found very low LDL was not clearly linked to higher all-cause death after adjustment, but the authors acknowledged residual confounding and uncertainty at the lowest levels [2]. This means very low cholesterol should not be assumed to be safe or unsafe without individual medical review.

Pancreatitis is an important safety concern in severe triglyceride disorders. Triglyceride-lowering drugs may help prevent it in some patients, but this is a specific clinical goal and not a reason to self-treat [4].

Limitations of Current Research

• Most sources are narrative reviews, which summarize other work and can reflect the authors’ judgment [1,3,4,5].
• This article is based on abstracts only. Full texts were not reviewed.
• Many emerging therapies lack large randomized outcome trials [3,4,5].
• Dialysis and advanced kidney disease remain underrepresented in the evidence [1].
• The cohort study relied on electronic health records and could not fully adjust for all differences between patients [2].

Frequently Asked Questions

Are injectable cholesterol medicines the same as statins?

No. Statins are usually taken by mouth and have a long track record. Injectable agents such as PCSK9 antibodies and inclisiran work through different pathways, and some are added to statins when extra LDL lowering is needed [1,3].

Do these treatments reduce heart attacks and strokes?

For many newer agents, the answer is not yet proven. Some lower LDL or triglycerides strongly, but outcome trials are still needed to confirm fewer heart events [3,4,5].

Why is kidney disease a special concern?

People with advanced kidney disease have high heart risk, yet they are often left out of trials. The dialysis paradox also means standard cholesterol assumptions may not apply [1].

Is a lower non-HDL cholesterol always better?

The cohort study suggested benefit with non-HDL cholesterol levels below 3.4 mmol/L after statin start, but it was observational and cannot set treatment targets for individuals [2].

Should I change my medicine based on this article?

No. Never stop or change a prescribed medicine without speaking to your clinician. Individual decisions depend on your full medical history.

Key Takeaways

• LDL cholesterol remains important, but researchers are studying other blood fats and risk factors.
• Observational data link lower LDL and non-HDL cholesterol after statin start with fewer heart events, but cause cannot be proven [2].
• Inclisiran strongly lowers LDL in trials, but heart outcome results are still pending [3].
• Triglyceride-targeted therapies show promise, especially for preventing pancreatitis in severe cases, but cardiovascular benefit is not yet established [4,5].
• People with advanced kidney disease need more research and careful, individualized care [1].

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Consult a qualified healthcare professional before making treatment decisions.

References

1. Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox. DOI: https://doi.org/10.1007/s10557-026-07934-y
2. Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study.. DOI: https://doi.org/10.1371/journal.pmed.1005012
3. Inclisiran-will it fulfill its promise?. DOI: https://doi.org/10.1016/j.numecd.2026.104848
4. Targeting Apolipoprotein C-III in Hypertriglyceridemia: Implications for Pancreatitis and Cardiovascular risk. DOI: https://doi.org/10.1007/s11883-026-01472-6
5. Targeting triglycerides for cardiovascular risk reduction.. DOI: https://doi.org/10.1007/s11739-026-04383-1